Agios Pharmaceuticals Inc (AGIO) - News Archive

: This article discusses recent advancements in treatment options for thalassemia, with a focus on the positive progress made with PYRUKYND (mitapivat). Agios Pharmaceuticals has reported significant milestones, includi...

In a significant move to enhance its market presence and address the needs of patients with rare blood clotting disorders, Agios Pharmaceuticals Inc. (NASDAQ: AGIO) announced a strategic partnership with Avanzanite. Thi...

Expanding Horizons in Rare Blood Disorders: Avanzanite and Agios Pharmaceuticals Forge a Strategic Alliance for PYRUKYND Launch The landscape of rare blood disorder treatment is experiencing a significant shift with the...

Agios Pharmaceuticals Inc. has announced promising results from the Phase 3 ACTIVATE-Kids study evaluating Mitapivat, a novel oral therapy, in children diagnosed with Pyruvate Kinase (PK) deficiency who are not regularl...

Agios Pharmaceuticals Reports Q4 and Full Year 2024 Financial Results, Advances Mitapivat for Thalassemia TreatmentAgios Pharmaceuticals Inc. a biopharmaceutical company focused on discovering and developing innovative...

: Agios Pharmaceuticals, Inc. announced the positive designation of mitapivat, an oral pyruvate kinase activator, as an orphan medicinal product for the treatment of sickle cell disease by the European Commission. The c...

Agios Pharmaceuticals Poised for Growth with FDA Approval of Vorasidenib: A $1.1 Billion WindfallIn a significant milestone for both Agios Pharmaceuticals and the broader biopharmaceutical industry, the recent FDA appro...

In recent developments concerning hemolytic anemias, Agios Pharmaceuticals has reported compelling results from multiple Phase 3 clinical studies investigating the therapeutic potential of Mitapivat. This article review...

Groundbreaking Phase 3 ENERGIZE Study Shows Promise for Non-Transfusion-Dependent Thalassemia Treatment: A Comprehensive Assessment CSIMarket.com is pleased to present an intriguing breakthrough in the treatment of non-...

Agios Pharmaceuticals Achieves Major Milestones in Thalassemia and Sickle Cell Disease ResearchAgios Pharmaceuticals, renowned for its innovative therapies targeting rare genetic diseases, has marked significant advance...

Agios Pharmaceuticals, a pioneering company in the field of cellular metabolism-based therapies, consolidates its groundbreaking research on rare blood conditions at the European Hematology Association (EHA) 2024 Hybrid...

The Phase 3 ENERGIZE study has recently analyzed the efficacy and safety of a promising new drug, Mitapivat, in patients with non-transfusion-dependent alpha or beta-thalassemia and released its ground-breaking results....

Biopharmaceutical company Agios has made a major breakthrough in the treatment of sickle cell disease, it revealed at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. Presenting the positive...

In a groundbreaking development, Agios Pharmaceuticals has recently announced the successful clinical proof-of-concept in a Phase 2a trial of their novel drug, AG-946, for the treatment of anemia in lower-risk Myelodysp...